DJIA 18,263.28 -22.46 -0.12%
NASDAQ 5,097.39 6.59 0.13%
S&P 500 2,128.67 -2.15 -0.10%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)

2.54 -0.05 (-1.74%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VVUS $2.54 -1.74%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.57
Previous Close $2.58
Daily Range $2.50 - $2.62
52-Week Range $2.22 - $5.52
Market Cap $263.2M
P/E Ratio -3.23
Dividend (Yield) $0.00 (0.0%)
Volume 597,323
Average Daily Volume 1,097,943
Current FY EPS -$0.83

Sector

Healthcare

Industry

Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker

A double dose of bad news for the obesity drugmaker.

Orexigen: Contrave Sales Flattening - Europe Needed To Spur Numbers

Vivus: Qsymia Sales Win The Week, But Is It Enough?

Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?

Why Shares of Orexigen Therapeutics, Inc. Cratered Today

Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.

Why It's Lights Out for Orexigen Therapeutics, Inc.

Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.

Vivus' Stendra To Get A Re-Launch

Many Pin Their Hopes On Vivus's Chances In Latin America

Vivus - Qsymia Script Sales Flat Again - Should Vivus Concentrate On Stendra?

Orexigen - Contrave Scripts Grow, But Reality On Revenue May Shock You

See More VVUS News...

VVUS's Top Competitors

VVUS $2.54 (-1.74%)
Current stock: VVUS
JNJ $101.38 (-1.02%)
Current stock: JNJ
NVS $103.85 (-0.90%)
Current stock: NVS
RHHBY $36.77 (-1.12%)
Current stock: RHHBY